Canary Capital amended its Staked INJ ETF proposal to list on Nasdaq instead of Cboe BZX, with the ticker INJC. The ETF aims to track the price of Injective (INJ) tokens it holds, with staking as a secondary goal, expecting to stake at least 90% of INJ under normal conditions. The trust is not yet effective and cannot trade shares until approved, with no set trading date. Fees include a 1.10% annual sponsor fee and up to 30% of staking rewards shared among service providers. Injective Foundation plans to buy up to $15 million in shares, paid in INJ tokens. The ETF would not be registered under the Investment Company Act, so it lacks certain investor protections.
Canary's Staked INJ ETF proposal offers context for cryptocurrency market watchers. For readers following crypto, here is Pluang's market snapshot as of Oct 31, 2026 03:21 WIB: of 50 major cryptocurrencies priced, 5 rose and 44 fell. Notable movers include CAKE at Rp33.989 with a 1-day change of -8.16%, EOS at Rp12.649 up 8.13%, and XTZ at Rp4.630 down 7.66%.
Philips has introduced the HyperVue Integrated System in the U.S., a fixed, single-room setup combining DeepOCT+NIRS imaging with X1-FFR physiology assessment for coronary interventions. This system is designed to streamline cath lab workflows by kee...
Atlas Copco Group completed Expansion Week in the US, unveiling three major manufacturing expansions in New York and South Carolina. The new facilities will increase production of oil-free compressors, dry vacuum pumps, and gas and process equipment,...
Mohawk Industries reported Q3 2026 net sales of $2.8 billion, up about 1%, driven by price increases offsetting lower volumes amid weak demand. Adjusted EPS rose 2% to $2.72, supported by productivity and pricing strategies. The company generated $39...
The global Drone as First Responder (DFR) market, valued at $3 billion in 2025, is projected to grow to $11 billion by 2033 at a 17.7% CAGR. Growth is fueled by advancements in automated drone-in-a-box systems, beyond visual line of sight (BVLOS) ope...
Alphatec Holdings lowered its 2026 revenue guidance from approximately $882 million to $862 million following its third-quarter results, citing lower biologics attachment rates, softer procedure volumes, and supply constraints. This $20 million reduc...
